Liraglutide and Renal Outcomes in Type 2 Diabetes: Results of the LEADER Trial

ASN 2016 High Impact Clinical Trial Johannes F. Mann, Kristine Brown Fandsen, Gilbert Daniels, Peter Kristensen, Michael Nauck, Steve Nissen, Stuart Pocock, Neil Poulter, Soren Rasmussen, William Steinberg, Mette Stockner, Bernard Zinman, Florian Baeres, Richard Bergenstal, Steve Marso, John Buse. Erlangen, Germany. Liraglutide, as compared to placebo, was studied in a RCT of 9340 high-risk type 2 diabetic patients to examine the impact on the primary composite outcome of nonfatal MI, nonfatal stroke, and cardiovascular death.  The secondary renal endpoint (composite of doubling serum creatinine, ESRD, death due to renal disease and decrease in albuminuria) was reported today. The renal outcome was reduced with a HR of 0.78 (0.67-.0.92, p = 0.003), predominantly driven by a reduction in albuminuria with HR 0.74 (p < 0.05).  There was no increased risk of AKI.   : Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75Years: A Randomized Clinical Trial Empagliflozin and Clinical Outcomes in Patients with Type 2 Diabetes and Chronic Kidney Disease Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes
Source: Nephrology Now - Category: Urology & Nephrology Authors: Tags: Clinical Trial Results Conference Alert Source Type: research